These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 33180128)

  • 1. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
    Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
    JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
    Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
    Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
    Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
    Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
    Yamagata A; Yokoyama T; Fukuda Y; Ishida T
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
    Murata D; Azuma K; Matama G; Zaizen Y; Matsuo N; Murotani K; Tokito T; Hoshino T
    Thorac Cancer; 2023 Jan; 14(1):73-80. PubMed ID: 36377039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database.
    Okada N; Hamano H; Yagi K; Niimura T; Aizawa F; Goda M; Zamami Y; Kitahara T; Ishizawa K
    Int J Clin Pharmacol Ther; 2024 Feb; 62(2):69-76. PubMed ID: 37969096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.
    Nishiyama N; Honda T; Sema M; Kawahara T; Jin Y; Natsume I; Chiaki T; Yamashita T; Tsukada Y; Taki R; Miyashita Y; Saito K; Tateishi T; Sakashita H; Miyazaki Y
    Int J Clin Oncol; 2020 Feb; 25(2):282-291. PubMed ID: 31720993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER.
    Koga K; Tasaka Y; Nawa H
    Biol Pharm Bull; 2024; 47(7):1296-1300. PubMed ID: 39010215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
    Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
    Murata D; Azuma K; Murotani K; Matsuo N; Matama G; Tokito T; Sasada T; Hoshino T
    Lung Cancer; 2023 Oct; 184():107351. PubMed ID: 37639819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study.
    Suzuki Y; Karayama M; Uto T; Fujii M; Matsui T; Asada K; Kusagaya H; Kato M; Matsuda H; Matsuura S; Toyoshima M; Mori K; Ito Y; Koyauchi T; Yasui H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
    J Thorac Oncol; 2020 Aug; 15(8):1317-1327. PubMed ID: 32289515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
    Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
    Petranovic M; McDermott S; Mercaldo S; Little BP; Graur A; Huang K; Fintelmann FJ; Digumarthy SR; Gainor JF
    Clin Lung Cancer; 2023 Dec; 24(8):682-688.e5. PubMed ID: 37758549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Patients with Interstitial Lung Disease: Significance of Radiological Pleuroparenchymal Fibroelastosis.
    Osaki M; Arai T; Sumikawa H; Takimoto T; Takeuchi N; Tamiya A; Okishio K; Inoue Y
    Oncology; 2023; 101(5):303-312. PubMed ID: 36689929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
    Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
    Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy.
    Kitahara Y; Inoue Y; Yasui H; Karayama M; Suzuki Y; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Funai K; Honda T; Misawa K; Miyake H; Takeuchi H; Inui N; Suda T
    Respir Res; 2024 Jan; 25(1):25. PubMed ID: 38200501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.
    Gemma A; Kusumoto M; Kurihara Y; Masuda N; Banno S; Endo Y; Houzawa H; Ueno N; Ohki E; Yoshimura A
    J Thorac Oncol; 2019 Apr; 14(4):672-682. PubMed ID: 30521972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.
    Shibaki R; Murakami S; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Kusumoto M; Yamamoto N; Ohe Y
    Cancer Immunol Immunother; 2020 Jan; 69(1):15-22. PubMed ID: 31745589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
    Delaunay M; Cadranel J; Lusque A; Meyer N; Gounant V; Moro-Sibilot D; Michot JM; Raimbourg J; Girard N; Guisier F; Planchard D; Metivier AC; Tomasini P; Dansin E; Pérol M; Campana M; Gautschi O; Früh M; Fumet JD; Audigier-Valette C; Couraud S; Dalle S; Leccia MT; Jaffro M; Collot S; Prévot G; Milia J; Mazieres J
    Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28798088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.